🔎 Trials Near Me

Utama › Leukemia Limfositik Kronik › Nebraska

Kajian klinikal Leukemia Limfositik Kronik di Nebraska

8 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi di Nebraska.

Bandar di Nebraska

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 2 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277231

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06528301

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • University Of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • University Of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876649

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.